DNA Microarray Prognosis for Rheumatoid Arthritis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current DNA-chip technologies face challenges in simultaneously analyzing a large number of genetic variations in a sensitive, specific, and reproducible manner, limiting their application in routine clinical diagnosis for conditions like Rheumatoid Arthritis (RA).

Innovation Solution

The development of a method using combinations of informative SNP variables and clinical variables, including anti-cyclic citrullinated peptide antibody levels, erythrocyte sedimentation rate, and other clinical markers, to prognose RA phenotypes, along with the use of DNA microarrays and computational methods to derive probability functions for predicting disease progression and treatment responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If DNA-chip technologies are used to analyze a large number of genetic variations, then the quantity of genetic data obtained increases, but the sensitivity, specificity, and reproducibility of the analysis deteriorate

Engineering Contradiction:

Improvenumber of genetic variations analyzedVSAvoidsensitivity and specificity of analysis

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent extracts and focuses on a specific subset of genetic variations (SNPs) that are most relevant to RA prognosis, rather than analyzing all possible genetic variations. By selecting only the most informative SNPs and combining them with clinical variables, the method maintains high sensitivity and specificity while analyzing a manageable number of genetic markers.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies different analysis strategies to different types of data (genetic vs. clinical variables) and uses weighted combinations to give appropriate importance to each variable type. This localized approach to data quality and analysis ensures that each variable contributes optimally to the overall prognostic accuracy.

Inventive Principle:

Principle #3Local quality

2Measurement precision

If multiple genetic and clinical variables are combined for prognosis, then the diagnostic precision improves, but the device and method complexity increases

Engineering Contradiction:

Improvediagnostic precisionVSAvoidmethod complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent merges genetic data (SNP variables) with clinical data (clinical variables) into a unified prognostic model. By combining these different types of variables and analyzing them together using statistical methods, the patent achieves higher diagnostic precision than would be possible with either data type alone.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent uses statistical models and computational algorithms as intermediaries to process and integrate the complex multi-variable data. These computational tools serve as mediators that transform raw genetic and clinical data into meaningful prognostic predictions, managing the complexity while maintaining precision.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If DNA microarrays are used for genotyping, then the productivity of genetic analysis increases, but the ease of operation and interpretation decreases

Engineering Contradiction:

Improvegenotyping throughputVSAvoidease of interpretation

Core Design Contradiction:

ProductivityVSEase of operation

Solution Approach 1:

The patent performs preliminary selection and validation of SNP variables before the actual prognostic analysis. By pre-identifying the most informative SNPs and establishing their relationships with clinical variables in advance, the method simplifies the interpretation process while maintaining high genotyping throughput using DNA microarrays.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent employs statistical models that provide feedback on the relationships between genetic and clinical variables, helping to interpret the complex data generated by DNA microarrays. This feedback mechanism translates raw genotyping data into clinically meaningful prognostic information.

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for accurate prediction of RA phenotypes and treatment outcomes, enhancing diagnostic precision and therapeutic decision-making by integrating genetic and clinical data, thereby improving the clinical utility of DNA microarrays in RA management.

Implementation Method 1

DNA-chips are often used to discriminate between alleles at genetic loci

Methodology Applied

Scientific EffectHybridization:

Data Source

PatentUS8712696B2Methods of prognosing a rheumatoid arthritis remission phenotype

Publication Date: 2014.04.29 PROGENIKA BIOPHARMA SA

AI summary

A method for prognosing a rheumatoid arthritis phenotype using the outcomes of selected single nucleotide polymorphisms (SNPs) and clinical variables. A method for genotyping multiple rheumatoid arthritis associated genetic variations comprising use of a DNA microrarray. A microarray for use in the described methods.